Cancer Immunology, Immunotherapy

, Volume 35, Issue 2, pp 92–96 | Cite as

Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy

  • Takashi Misaki
  • Yoshihiro Watanabe
  • Yasuhiro Iida
  • Akinari Hidaka
  • Kanji Kasagi
  • Hideyuki Fukushima
  • Junji Konishi
Original articles


To elucidate the mechanism of action for intratumoral injection of immunopotentiators, infiltrating mononuclear cells and tumor necrosis factor (TNF) were assayed by immunostaining tissue samples of differentiated thyroid cancer resected with or without presurgical local application of OK-432, a streptococcal preparation. Frozen sections of resected specimens were stained with monoclonal antibodies using either a conventional or a modified immunoperoxidase method. The tumors injected with OK-432 showed increased T lymphocyte infiltration and HLA-DR expression on cancer cells as compared to the non-injected controls. Among these T cells, the CD4+ subset was more numerous than the CD8+ population. In four out of the seven cases constituting the injected group, numerous TNF-positive cells were seen in clusters or lines as well as scattered, while none of the seven cases in the control group was associated with a considerable amount of these cells. In their morphology and distribution pattern, these TNF-positive cells appeared to be of macrophage lineage. Thus local injection of OK-432 in thyroid cancer was shown to recruit T lymphocytes of predominantly the CD4+ subset and to induce in situ production of TNF, a known potent tumoricidal cytokine. The present data warrant further studies in this direction besides wider clinical intratumoral application of the reagent.

Key words

T lymphocyte Tumor necrosis factor Thyroid cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN (1985) Human tumor necrosis factor. J Biol Chem 260: 2345Google Scholar
  2. 2.
    Akura Y, Tanaka N, Kobayashi G, Gotoh A, Gouchi A, Kamitani S, Gangi J, Orita K (1986) The effects of intratumoral OK-432 injection in gastric cancer patients. In: Tobe T (ed), New applications of OK-432. Excerpta Medica, Tokyo, p 75Google Scholar
  3. 3.
    Chensue SW, Remick DG, Shmyr-Forsch C, Beals TF, Kunkel S (1988) Immunohistochemical demonstration of cytoplasmic and membrane-associated tumor necrosis factor in murine macrophages. Am J Pathol 133: 564Google Scholar
  4. 4.
    Hojo H, Hashimoto Y (1981) Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432). Gann 72: 692Google Scholar
  5. 5.
    Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N (1985) Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol 7: 263Google Scholar
  6. 6.
    Kokunai I, Shimano T, Sekimoto K, Takeda T, Kobayashi T, Yayoi E, Yamamoto A, Mori T (1986) Induction of tumor necrosis factor by administration of OK-432 in cancer patients. J Clin Lab Immunol 21: 169Google Scholar
  7. 7.
    Kraiem Z, Sobel E, Sadeh O, Kinarty S, Lahat N (1990) Effects of γ-interferon on DR antigen expression, growth, 3,5,3′-triiodothyronine secretion, iodide uptake, and cyclic adenosine 3′,5′-monophosphate accumulation in cultured human thyroid cells. J Clin Endocrinol Metab 71: 817Google Scholar
  8. 8.
    Misaki T, Dokoh S (1990) Two cases of differentiated thyroid cancer treated with local injection of OK-432 (in Japanese). Ther Res 11: 3779Google Scholar
  9. 9.
    Misaki T, Konishi J, Nakashima T, Iida Y, Kasagi K, Endo K, Uchiyama T, Kuma K, Torizuka K (1985) Immunohistological phenotyping of thyroid infiltrating lymphocytes in Graves' disease and Hashimoto's thyroiditis. Clin Exp Immunol 60: 104Google Scholar
  10. 10.
    Misaki T, Tramontano D, Ingbar SH (1988) Effects of rat γ- and non-γ-interferons on the expression of Ia antigen, growth, and differentiated functions of FRTL5 cells. Endocrinology 123: 2849Google Scholar
  11. 11.
    Miwa H, Gohchi A, Moriyasu F, Orita K (1984) Increase in T cell infiltration in carcinoma tissue and regional lymph node reaction to gastric cancer after local injection of immunomodulators before gastrectomy. In: Aoki T, Tsubura E, Urushizaki I (eds) Manipulation of host defence mechanisms. Excerpta Medica, Amsterdam, p 13Google Scholar
  12. 12.
    Oettgen HF, Old LJ (1987) Tumor necrosis factor. In: Rosenberg SA, Herrman S, DeVita VT Jr (eds) Important advances in oncology. Lippincott, Philadelphia, p 105Google Scholar
  13. 13.
    Saito M, Ebina T, Koi M, Yamaguchi T, Kawade Y, Ishida N (1982) Induction of interferon-γ in mouse spleen cells by OK-432, a preparation ofStreptococcus pyogenes. Cell Immunol 68: 187Google Scholar
  14. 14.
    Saito M, Nanjo M, Aonuma E, Noda T, Nakadate I, Ebina T, Ishida N (1984) Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer 33: 271Google Scholar
  15. 15.
    Sawaki S, Tsukuda M, Mitarai K (1986) Clinical evaluation of nonspecific immunotherapy with OK-432 for head and neck cancer. In: Ota K (ed) Clinical application of OK-432 for control of cancer. Excerpta Medica, Tokyo, p 255Google Scholar
  16. 16.
    Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, Shiga T (1987) Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 56: 803Google Scholar
  17. 17.
    Stötter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell susceptability to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol 142: 1767Google Scholar
  18. 18.
    Sugenoya A, Usuda N, Adachi W, Kaneko G, Nagata T, Iida F (1988) Immunohistochemical studies on local antitumor effects of streptococcal immunopotentiator, OK-432, in human solid malignant tumors. Arch Pathol Lab Med 112: 545Google Scholar
  19. 19.
    Umesaki N, Ooshita Y, Kawabata M, Sako H, Sugawa T (1986) Experimental and clinical efficacy of locally administered OK-432, in particular against gynecological cancer. In: Tobe T (ed) New applications of OK-432. Excerpta Medica, Tokyo, p 102Google Scholar
  20. 20.
    Urban JL, Rothstein JL, Shephard MH, Schreiber H (1987) Tumornecrosis factor: a potent mediator of macrophage-dependant tumorcell killing. Haematol Blood Trans 31: 351Google Scholar
  21. 21.
    Watanabe N, Niitsu Y, Yamauchi N, Neda H, Sone H, Urushizaki I, Yamamoto A, Nagamuta M, Sugawara Y (1988) Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients. Immunopharmacol Immunotoxicol 10: 53Google Scholar
  22. 22.
    Watanabe Y, Yamada T, Hashizume Y, Iwa T (1986) Clinical value of immunotherapy with the streptococcal preparation, OK-432 for lung cancer: a randomized study. In: Ota K (ed) Clinical application of OK-432 for control of cancer. Excerpta Medica, Tokyo, p 105Google Scholar
  23. 23.
    Yagita A, Watanabe Y, Ito H, Tatekawa I, Saito M, Ishida N (1986) Relationship between HLA antigens and immune response in Su-PS skin tests, and between the H-2 system and blastogenic activity in the presence of OK-432. In: Hoshino T (ed) Immunopharmacological aspects of OK-432 in humans. Excerpta Medica, Tokyo, p 225Google Scholar
  24. 24.
    Yamamoto A, Nagamuta M, Usami H, Sugawara Y, Watanabe N, Niitsu Y, Urushizaki I (1986) Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation. Immunopharmacology 11: 79Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Takashi Misaki
    • 1
  • Yoshihiro Watanabe
    • 2
  • Yasuhiro Iida
    • 1
  • Akinari Hidaka
    • 1
  • Kanji Kasagi
    • 1
  • Hideyuki Fukushima
    • 2
  • Junji Konishi
    • 1
  1. 1.Department of Nuclear MedicineKyoto University School of MedicineKyotoJapan
  2. 2.Department of OtonasolaryngologyKyoto University School of MedicineKyotoJapan

Personalised recommendations